Kenvue Inc. Stock Price, News & Analysis

Kenvue (NYSE: KVUE), the world's largest pure-play consumer health company, has announced a dividend increase. The company's Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock, representing a 1.2% increase from the previous quarter.

The dividend will be payable on August 27, 2025, to shareholders of record as of August 13, 2025. Kenvue's portfolio includes well-known brands such as Aveeno, BAND-AID, Johnson's, Listerine, Neutrogena, and Tylenol.

Kenvue (NYSE: KVUE), the world's largest pure-play consumer health company, will release its Q2 2025 financial results before market open on August 7, 2025. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the results.

Investors can access the conference call by dialing 877-407-8835 (U.S.) or +1 201-689-8779 (international). A live webcast will be available at investors.kenvue.com, with a replay accessible after the event.

Kenvue (NYSE:KVUE), the world's largest pure-play consumer health company, announced significant leadership changes and strategic initiatives. The company has appointed Kirk Perry as Interim CEO, replacing Thibaut Mongon, effective immediately. Perry brings over 30 years of consumer products and technology experience.

The Board has initiated a comprehensive strategic review to unlock shareholder value, considering portfolio optimization and operational improvements. Additionally, Kenvue released preliminary Q2 2025 results showing a 4.0% decline in net sales and organic sales decrease of 4.2%, with adjusted diluted EPS expected between $0.28 and $0.29.

The company will provide updated full-year 2025 guidance during its complete Q2 earnings release on August 7, 2025.

Kenvue (NYSE: KVUE), known for brands like Tylenol, Neutrogena, and Listerine, has achieved a significant milestone by making its debut on the Fortune 500 list at position 281, with annual sales of $15.5 billion in 2024. As a newly independent company, Kenvue operates in over 165 countries with a workforce of 20,000 employees, reaching approximately 1.2 billion consumers daily through its Essential Health, Self Care, and Skin Health & Beauty brands. CEO Thibaut Mongon highlighted this achievement as validation of the company's dedication and progress toward becoming the global leader in consumer health. The company focuses on combining scientific expertise with human insights and advanced technology to advance its wellness mission.

Kenvue Inc. (NYSE: KVUE), known for brands like Neutrogena®, Listerine®, Aveeno®, and Tylenol®, has announced its participation in the Deutsche Bank's dbAccess Global Consumer Conference in Paris, France. The company's leadership team, including CEO Thibaut Mongon, CFO Amit Banati, and Group President Carlton Lawson, will engage in a fireside chat on June 3, 2025, at 6:00 a.m. ET / 12:00 p.m. CET. Investors can access a live webcast of the session on investors.kenvue.com, with a replay available after the event.

Kenvue (NYSE: KVUE) has announced its global Kenvue Cares Week initiative, showcasing significant community engagement across 21 markets on six continents. The company's employees, known as Kenvuers, are contributing over 5,000 volunteer hours and assembling approximately 22,000 hygiene kits containing more than 110,000 products from brands like Neutrogena®, Listerine®, and Johnson's® Baby.

The program, which has seen a fourfold increase in site participation since its inaugural year, involves partnerships with organizations like Save the Children, Heart to Heart International, and various local nonprofits. Activities include disaster relief efforts, environmental initiatives, and community support programs across North America, Latin America, Europe, Middle East, Africa, and Asia-Pacific regions.

Kenvue (NYSE: KVUE) reported its Q1 2025 financial results, showing a 3.9% decrease in net sales and 1.2% decline in organic sales. The company's performance was impacted by foreign currency headwinds of 2.7%. Key financial metrics include: • Gross profit margin increased to 58.0% from 57.6% • Operating income margin rose to 14.9% from 14.1% • Diluted EPS improved to $0.17 from $0.15 • Adjusted diluted EPS decreased to $0.24 from $0.28 For FY2025, Kenvue updated its outlook to reflect foreign exchange rates and tariff impacts, projecting: • Net sales growth of +1% to +3% • Organic sales growth of +2% to +4% • Expected decline in adjusted operating income margin • Adjusted diluted EPS to remain flat year-over-year

Kenvue (NYSE: KVUE) has appointed Amit Banati as its new Chief Financial Officer, effective May 12, 2025. Banati, a 30-year veteran in consumer products finance and operations, will succeed Paul Ruh and oversee Finance and Strategy functions. Banati joins from Kellanova (previously Kellogg Company) where he served as Vice Chairman and CFO, with prior experience at Kraft Foods, Cadbury Schweppes, and Procter & Gamble.

The new CFO brings significant international operations experience, particularly in Asia Pacific, Middle East, India, and Africa. His focus will be on supporting revenue growth through data management, resource allocation, margin improvement, strengthening cash flow, and fostering greater agility in business planning and financial forecasting.

Kenvue (NYSE: KVUE), the world's largest pure-play consumer health company by revenue, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, before market open. The company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss the results.

Investors can access the conference call by dialing 877-407-8835 (U.S.) or +1 201-689-8779 (international). A live webcast will be available at investors.kenvue.com, with a replay accessible after the event.

Kenvue's portfolio includes renowned brands such as Aveeno, BAND-AID, Johnson's, Listerine, Neutrogena, and Tylenol, which are science-backed and recommended by healthcare professionals globally.